Natera, Inc. (NTRA)
NASDAQ: NTRA · IEX Real-Time Price · USD
102.67
+0.52 (0.51%)
At close: Jul 26, 2024, 4:00 PM
101.27
-1.40 (-1.36%)
After-hours: Jul 26, 2024, 4:48 PM EDT
Natera Revenue
Natera had revenue of $367.74M in the quarter ending March 31, 2024, with 52.11% growth. This brings the company's revenue in the last twelve months to $1.21B, up 39.26% year-over-year. In the year 2023, Natera had annual revenue of $1.08B with 31.99% growth.
Revenue (ttm)
$1.21B
Revenue Growth
+39.26%
P/S Ratio
10.43
Revenue / Employee
$367,008
Employees
3,293
Market Cap
12.61B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 1.08B | 262.35M | 31.99% |
Dec 31, 2022 | 820.22M | 194.74M | 31.13% |
Dec 31, 2021 | 625.49M | 234.48M | 59.97% |
Dec 31, 2020 | 391.01M | 88.68M | 29.33% |
Dec 31, 2019 | 302.33M | 44.67M | 17.34% |
Dec 31, 2018 | 257.65M | 48.03M | 22.91% |
Dec 31, 2017 | 209.63M | -2.89M | -1.36% |
Dec 31, 2016 | 212.51M | 22.16M | 11.64% |
Dec 31, 2015 | 190.36M | 31.07M | 19.50% |
Dec 31, 2014 | 159.29M | 104.12M | 188.72% |
Dec 31, 2013 | 55.17M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Viatris | 15.36B |
DaVita | 12.34B |
Smith & Nephew | 5.55B |
Dr. Reddy's Laboratories | 3.35B |
Revvity | 2.73B |
Royalty Pharma | 2.24B |
Insulet | 1.78B |
Sarepta Therapeutics | 1.40B |
NTRA News
- 12 hours ago - New MultiCenter Prospective Study Demonstrates Signatera's Clinical Utility in Merkel Cell Carcinoma - Business Wire
- 23 days ago - Natera to Present at the 28th International Conference on Prenatal Diagnosis and Therapy - Business Wire
- 4 weeks ago - Natera Announces DECIPHER: A Phase II, Single-Arm Adjuvant Trial in Gastroesophageal Cancer - Business Wire
- 5 weeks ago - Natera Launches Differentiated New Feature for Prospera™ Heart Test, Enhancing Detection of Rejection for Transplant Patients - Business Wire
- 7 weeks ago - Natera to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 2 months ago - Natera Presents Latest in Transplant Innovation Data Across Multiple Organs at ATC 2024 - Business Wire
- 2 months ago - Natera to Present at the 2024 Leerink Partners Healthcare Crossroads Conference - Business Wire
- 2 months ago - Natera Announces New MRD Data in Multiple Tumor Types, to be Presented at ASCO Annual Meeting - Business Wire